# Nucleosides And Darunavir/Dolutegravir In Africa

> **NCT03988452** · PHASE3 · UNKNOWN · sponsor: **Makerere University** · enrollment: 465 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** Darunavir
- **DRUG:** Ritonavir
- **DRUG:** Dolutegravir
- **DRUG:** Zidovudine
- **DRUG:** Tenofovir
- **DRUG:** Lamivudine

## Key facts

- **NCT ID:** NCT03988452
- **Lead sponsor:** Makerere University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-30
- **Primary completion:** 2020-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 465 (ACTUAL)
- **Last updated:** 2020-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03988452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03988452, "Nucleosides And Darunavir/Dolutegravir In Africa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03988452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*